Atea Pharmaceuticals's top three insider shareholders as of June 09, 2026 are Jean-Pierre Sommadossi (President, Ceo, And Chairman, 5.87Mn shares), Jean-Pierre Sommadossi (President, Ceo, And Chairman, 767.83K shares), Janet Mj Hammond (Chief Development Officer, 127.67K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, Ceo, And Chairman | 0 | 5,866,025 | 19 Sep, 2024 |
| Barbara Gayle Duncan | - | 62,750 | 0 | 24 Jun, 2025 |
| Polly A. Murphy | - | 86,045 | 0 | 24 Jun, 2025 |
| Maria Arantxa Horga | Chief Medical Officer | 96,086 | 0 | 03 Feb, 2026 |
| Bruno Lucidi | - | 112,750 | 0 | 24 Jun, 2025 |
| John Vavricka | Chief Commercial Officer | 82,594 | 0 | 03 Feb, 2026 |
| Janet Mj Hammond | Chief Development Officer | 127,665 | 0 | 03 Feb, 2026 |
| Jerome M. Adams | - | 62,750 | 0 | 24 Jun, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | A | 58,050 | - | 141,801 | D | M |
| 31 Jan, 2026 | John Vavricka | Common Stock | A | 42,083 | - | 94,164 | D | M |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | A | 272,983 | - | 573,923 | D | M |
| 31 Jan, 2026 | John Vavricka | Common Stock | A | 42,083 | - | 94,164 | D | M |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | A | 272,983 | - | 573,923 | D | M |
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | A | 51,283 | - | 112,159 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | A | 58,050 | - | 141,801 | D | M |
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | A | 51,283 | - | 112,159 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | D | 14,136 | $4.24 | 127,665 | D | F |
| 31 Jan, 2026 | John Vavricka | Common Stock | D | 11,570 | $4.24 | 82,594 | D | F |
| 31 Jan, 2026 | Janet Mj Hammond | Common Stock | D | 14,136 | $4.24 | 127,665 | D | F |
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | D | 16,073 | $4.24 | 96,086 | D | F |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | D | 106,093 | $4.24 | 467,830 | D | F |
| 31 Jan, 2026 | Jean-Pierre Sommadossi | Common Stock | D | 106,093 | $4.24 | 467,830 | D | F |
| 31 Jan, 2026 | John Vavricka | Common Stock | D | 11,570 | $4.24 | 82,594 | D | F |
| 31 Jan, 2026 | Maria Arantxa Horga | Common Stock | D | 16,073 | $4.24 | 96,086 | D | F |
| 31 Jan, 2026 | Janet Mj Hammond | Restricted Stock Units | D | 46,800 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Janet Mj Hammond | Restricted Stock Units | D | 46,800 | $0.00 | 0 | D | M |
| 03 Feb, 2026 | Jean-Pierre Sommadossi | Common Stock | A | 300,000 | $1.24 | 767,830 | D | M |
| 31 Jan, 2026 | Maria Arantxa Horga | Restricted Stock Units | D | 41,533 | $0.00 | 0 | D | M |